Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387327007> ?p ?o ?g. }
- W4387327007 abstract "Methylxanthines, including caffeine, theophylline, and aminophylline, work as stimulants of the respiratory drive, and decrease apnea of prematurity, a developmental disorder common in preterm infants. In particular, caffeine has been reported to improve important clinical outcomes, including bronchopulmonary dysplasia (BPD) and neurodevelopmental disability. However, there is uncertainty regarding the efficacy of caffeine compared to other methylxanthines.To assess the effects of caffeine compared to aminophylline or theophylline in preterm infants at risk of apnea, with apnea, or in the peri-extubation phase.We searched CENTRAL, MEDLINE, Embase, Epistemonikos, the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), and clinicaltrials.gov in February 2023. We also checked the reference lists of relevant articles to identify additional studies.Studies: randomized controlled trials (RCTs) and quasi-RCTs Participants: infants born before 34 weeks of gestation for prevention and extubation trials, and infants born before 37 weeks of gestation for treatment trials Intervention and comparison: caffeine versus theophylline or caffeine versus aminophylline. We included all doses and duration of treatment.We used standard methodological procedures expected by Cochrane. We evaluated treatment effects using a fixed-effect model with risk ratio (RR), risk difference (RD), and 95% confidence intervals (CI) for categorical data, and mean, standard deviation, and mean difference for continuous data. We used the GRADE approach to evaluate the certainty of evidence.We included 22 trials enrolling 1776 preterm infants. The indication for treatment was prevention of apnea in three studies, treatment of apnea in 13 studies, and extubation management in three studies. In three studies, there were multiple indications for treatment, and in one study, the indication for treatment was unclear. In 19 included studies, the infants had a mean gestational age between 28 and 32 weeks and a mean birth weight between 1000 g and 1500 g. One study's participants had a mean gestational age of more than 32 weeks, and two studies had participants with a mean birth weight of 1500 g or more. Caffeine administrated for any indication may result in little to no difference in all-cause mortality prior to hospital discharge compared to other methylxanthines (RR 1.12, 95% CI 0.68 to 1.84; RD 0.02, 95% CI -0.05 to 0.08; 2 studies, 396 infants; low-certainty evidence). Only one study enrolling 79 infants reported components of the outcome moderate to severe neurodevelopmental disability at 18 to 26 months. The evidence is very uncertain about the effect of caffeine on cognitive developmental delay compared to other methylxanthines (RR 0.17, 95% CI 0.02 to 1.37; RD -0.12, 95% CI -0.24 to 0.01; 1 study, 79 infants; very low-certainty evidence). The evidence is very uncertain about the effect of caffeine on language developmental delay compared to other methylxanthines (RR 0.76, 95% CI 0.37 to 1.58; RD -0.07, 95% CI -0.27 to 0.12; 1 study, 79 infants; very low-certainty evidence). The evidence is very uncertain about the effect of caffeine on motor developmental delay compared to other methylxanthines (RR 0.50, 95% CI 0.13 to 1.96; RD -0.07, 95% CI -0.21 to 0.07; 1 study, 79 infants; very low-certainty evidence). The evidence is very uncertain about the effect of caffeine on visual and hearing impairment compared to other methylxanthines. At 24 months of age, visual impairment was seen in 8 out of 11 infants and 10 out of 11 infants in the caffeine and other methylxanthines groups, respectively. Hearing impairment was seen in 2 out of 5 infants and 1 out of 1 infant in the caffeine and other methylxanthines groups, respectively. No studies reported the outcomes cerebral palsy, gross motor disability, and mental development. Compared to other methylxanthines, caffeine may result in little to no difference in BPD/chronic lung disease, defined as 28 days of oxygen exposure at 36 weeks' postmenstrual age (RR 1.40, 95% CI 0.92 to 2.11; RD 0.04, 95% CI -0.01 to 0.09; 3 studies, 481 infants; low-certainty evidence). The evidence is very uncertain about the effect of caffeine on side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of methylxanthines compared to other methylxanthines (RR 0.17, 95% CI 0.02 to 1.32; RD -0.29, 95% CI -0.57 to -0.02; 1 study, 30 infants; very low-certainty evidence). Caffeine may result in little to no difference in duration of hospital stay compared to other methylxanthines (median (interquartile range): caffeine 43 days (27.5 to 61.5); other methylxanthines 39 days (28 to 55)). No studies reported the outcome seizures.Although caffeine has been shown to improve important clinical outcomes, in the few studies that compared caffeine to other methylxanthines, there might be little to no difference in mortality, bronchopulmonary dysplasia, and duration of hospital stay. The evidence is very uncertain about the effect of caffeine compared to other methylxanthines on long-term development and side effects. Although caffeine or other methylxanthines are widely used in preterm infants, there is little direct evidence to support the choice of which methylxanthine to use. More research is needed, especially on extremely preterm infants born before 28 weeks of gestation. Data from four ongoing studies might provide more evidence on the effects of caffeine or other methylxanthines." @default.
- W4387327007 created "2023-10-05" @default.
- W4387327007 creator A5036299725 @default.
- W4387327007 creator A5038573927 @default.
- W4387327007 creator A5049297300 @default.
- W4387327007 creator A5051439307 @default.
- W4387327007 creator A5091361092 @default.
- W4387327007 date "2023-10-04" @default.
- W4387327007 modified "2023-10-11" @default.
- W4387327007 title "Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants" @default.
- W4387327007 cites W105855231 @default.
- W4387327007 cites W1509441537 @default.
- W4387327007 cites W1524533165 @default.
- W4387327007 cites W1531021750 @default.
- W4387327007 cites W1552549216 @default.
- W4387327007 cites W1599121529 @default.
- W4387327007 cites W1714664531 @default.
- W4387327007 cites W1964337652 @default.
- W4387327007 cites W1971367896 @default.
- W4387327007 cites W1973653539 @default.
- W4387327007 cites W1983974637 @default.
- W4387327007 cites W1989453462 @default.
- W4387327007 cites W2005980377 @default.
- W4387327007 cites W2007220595 @default.
- W4387327007 cites W2009301083 @default.
- W4387327007 cites W2012355941 @default.
- W4387327007 cites W2019549525 @default.
- W4387327007 cites W2021483138 @default.
- W4387327007 cites W2022023457 @default.
- W4387327007 cites W2022167001 @default.
- W4387327007 cites W2030294399 @default.
- W4387327007 cites W2031755929 @default.
- W4387327007 cites W2033693083 @default.
- W4387327007 cites W2043549021 @default.
- W4387327007 cites W2046224781 @default.
- W4387327007 cites W2049224179 @default.
- W4387327007 cites W2053058340 @default.
- W4387327007 cites W2057070985 @default.
- W4387327007 cites W2061831144 @default.
- W4387327007 cites W2063283365 @default.
- W4387327007 cites W2067292954 @default.
- W4387327007 cites W2068861236 @default.
- W4387327007 cites W2070295320 @default.
- W4387327007 cites W2072740770 @default.
- W4387327007 cites W2073632755 @default.
- W4387327007 cites W2080037849 @default.
- W4387327007 cites W2081373368 @default.
- W4387327007 cites W2087855943 @default.
- W4387327007 cites W2095394581 @default.
- W4387327007 cites W2097550443 @default.
- W4387327007 cites W2098254806 @default.
- W4387327007 cites W2098314489 @default.
- W4387327007 cites W2110607856 @default.
- W4387327007 cites W2114235313 @default.
- W4387327007 cites W2123152475 @default.
- W4387327007 cites W2127164101 @default.
- W4387327007 cites W2130249957 @default.
- W4387327007 cites W2157823046 @default.
- W4387327007 cites W2158625981 @default.
- W4387327007 cites W2164964624 @default.
- W4387327007 cites W2168129634 @default.
- W4387327007 cites W2185037608 @default.
- W4387327007 cites W2254337918 @default.
- W4387327007 cites W2264938409 @default.
- W4387327007 cites W2342027750 @default.
- W4387327007 cites W2353797840 @default.
- W4387327007 cites W2413690311 @default.
- W4387327007 cites W2414072545 @default.
- W4387327007 cites W2414399669 @default.
- W4387327007 cites W2415153782 @default.
- W4387327007 cites W2416995239 @default.
- W4387327007 cites W2463971168 @default.
- W4387327007 cites W2465710460 @default.
- W4387327007 cites W2508025527 @default.
- W4387327007 cites W2545458768 @default.
- W4387327007 cites W2551986483 @default.
- W4387327007 cites W2567362164 @default.
- W4387327007 cites W2604568423 @default.
- W4387327007 cites W2613242965 @default.
- W4387327007 cites W2742880550 @default.
- W4387327007 cites W2757886819 @default.
- W4387327007 cites W2776831375 @default.
- W4387327007 cites W2788435418 @default.
- W4387327007 cites W2793635904 @default.
- W4387327007 cites W2795325008 @default.
- W4387327007 cites W2821168934 @default.
- W4387327007 cites W2887518291 @default.
- W4387327007 cites W2910308657 @default.
- W4387327007 cites W2948793545 @default.
- W4387327007 cites W2964716412 @default.
- W4387327007 cites W3012861610 @default.
- W4387327007 cites W3022903699 @default.
- W4387327007 cites W3048480974 @default.
- W4387327007 cites W3095902429 @default.
- W4387327007 cites W3125296572 @default.
- W4387327007 cites W3148465273 @default.
- W4387327007 cites W4248251600 @default.
- W4387327007 cites W4328125323 @default.
- W4387327007 cites W4364362702 @default.
- W4387327007 cites W4387327007 @default.